Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders



Page Path
HOME > J Mov Disord > Volume 4(1); 2011 > Article
Original Article
Orthostatic Hypotension in Drug-Naïve Patients with Parkinson’s Disease
Hyo-Jin Bae, Sang-Myung Cheon, Jae Woo Kim
Journal of Movement Disorders 2011;4(1):33-37.
Published online: April 30, 2011

Department of Neurology, Dong-A University School of Medicine, Busan, Korea

Corresponding author: Sang-Myung Cheon, MD, Department of Neurology, Dong-A University, School of Medicine, 3-1 Dongdaesin-dong, Seo-gu, Busan 607-020, Korea, Tel +82-51-240-5266, Fax +82-51-244-8338, E-mail
• Received: September 27, 2010   • Accepted: January 19, 2011

Copyright © 2011 The Korean Movement Disorder Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 61 Download
  • 12 Crossref
  • Background and Purpose
    Orthostatic hypotension (OH) is known to be present even in patients with early Parkinson’s disease (PD). To affirm the presence of OH and find correlation between OH and other dysautonomic symptoms in PD, this study has done in newly-diagnosed PD patients.
  • Methods
    Forty-five non-demented patients with no prior history of treatment for PD were recruited (17 men, 63.8 ± 10.1 years of age). All the patients were evaluated for OH before starting medications. Autonomic symptoms were evaluated with structured questionnaires. Clinical characteristics of PD were evaluated (median Hoehn and Yahr stage 2.0 (1–3), 1.3 ± 1.1 years of disease duration), and comorbid medical conditions that could affect blood pressure were also recorded.
  • Results
    OH was prevalent, and eighteen patients (40%) showed orthostatic hypotension, and twenty-seven (60%) did not (normotensive group). There was no significant difference in demographic and clinical characteristics between groups. The presence or severity of symptoms of autonomic dysfunction in the OH group also not differed from those of the normotensive group.
  • Conclusions
    OH was prevalent even in the early stage of PD, and was not related to presence or severity of any other symptoms of autonomic dysfunction. Our findings suggest that clinicians should pay attention to OH from the early stage of disease.
Clinically, Parkinson’s disease (PD) is mainly characterized by motor symptoms such as bradykinesia, rigidity, tremor, and postural instability. However, patients with PD may also experience many complaints beyond motor symptoms, which are referred to as non-motor symptoms.1 The non-motor symptoms of PD are very diverse, including neuropsychiatric symptoms, sleep disturbances, sensory symptoms, and dysautonomic symptoms.2 It has become increasingly apparent that non-motor symptoms have a quite considerable impact on the quality of life of PD patients.1
Impaired cardiovascular response to postural changes, particularly orthostatic hypotension (OH) is considered an important clinical and even diagnostic feature for the multiple system atrophy or pure autonomic failure.3,4 In PD, OH was thought to develop later in the disease course or only in more severe cases often in elderly patients.57 Moreover, OH has been thought to be a side effect of anti-parkinsonian medications, like levodopa and dopamine agonists.812 However, it is accepted that OH is also a common finding even in the early stages of PD.13,14
The authors evaluated OH among newly-diagnosed PD patients and the relationship between OH and other symptoms of autonomic dysfunctions in patients.
We studied 45 selected PD patients without dementia. The subjects had been diagnosed as PD for the first time or diagnosed as PD by other clinicians but had never been treated before. The diagnosis of PD was established according to the criteria of the United Kingdom Parkinson’s Disease Society Brain Bank.15 We excluded atypical or secondary parkinsonisms, and the diagnosis was confirmed during the follow up visits for more than 6 months. Comorbid medical conditions that could affect blood pressure were also evaluated, which included hypertension, diabetes mellitus, and benign prostatic hypertrophy.
Evaluation of parkinsonian symptoms
Severity and stage of parkisonism were rated using the unified Parkinson’s disease rating scale, the Hoehn and Yahr stage and the Modified Schwab and England activities of daily living.
Evaluation of orthostatic hypotension and autonomic dysfunction
All patients were evaluated for the presence of OH, regardless of symptoms of orthostatic dizziness or syncope. To avoid the blood pressure lowering effect of dopaminergic drugs, all patients evaluated for OH before medication. OH was measured by monitoring systolic and diastolic blood pressure and heart rate. After a 10 minute period of lying down, systolic and diastolic blood pressures were checked in the first, third, and fifth minutes after standing up. If the patient could not stand up by his or herself, a tilt table was used. OH was defined as a drop in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg at anytime following standing up.
Comprehensive assessment of autonomic dysfunction was also assessed using a systematized autonomic dysfunction questionnaire (ADQ).3 The ADQ covered gastrointestinal symptoms, urinary symptoms, sexual dysfunction, cardiovascular symptoms and thermoregulatory symptoms. The severity or frequency of each of the symptoms was expressed as scores (Table 1).
SPSS version 14 for Windows was used for statistical calculations. Mann-Whitney and Chi tests were employed to analyze intergroup difference. Statistical significance was declared at the p < 0.05 range.
General and clinical characteristics of patients
The subjects (17 men and 28 women, age of 63.8 ± 10.1 years) showed mild disease [median Hoehn and Yahr stage 2.0 (1–3)] with 1.3 ± 1.1 years of disease duration. Twenty-two patients had comorbid disease, which could affect blood pressure. Hypertension (20/45 patients) was the most common, followed by diabetes (7/45) and benign prostatic hyperplasia (1/45).
Eighteen patients showed OH (OH group, 8 men, age 61.3 ± 10.8 years) and twenty-seven patients (normotensive group, 9 men, age 65.5 ± 9.4 years) did not. Patients without OH were older and showed shorter duration of education, but those demographic characteristics were not significantly different between groups (Table 2). Parkinsonian symptoms and daily activities of the patients also showed no significant difference between groups (Table 2).
Symptoms of autonomic dysfunctions in patients
Many dysautonomic symptoms were accompanied with OH in patients, and all the patients had more than two of those symptoms (Table 3). Urinary symptoms were most common and followed by sexual symptoms. Although urinary incontinence was more prevalence in OH group, it did not reach statistical significance. The presence of OH was not related with the presence of other symptoms.
Total score in the ADQ was slightly increased in patients with OH compared to that of patients without OH (Table 4). However, the differences did not reach statistical significance. In spite of the insignificant difference, the scores of all domains in the OH group were higher than those of the normotensive group. However, even in the questions of cardiovascular symptoms, orthostatic dizziness and history of syncope, there was no difference between groups. Only eight patients complained of orthostatic dizziness and four of those patients showed OH.
Abnormal cardiovascular regulation, including orthostatic hypotension was frequently expressed in various stages of PD patients.16,17 The cardiovascular autonomic disturbances are following the gastrointestinal symptoms in frequency, but they have a higher impact on the quality of life in PD patients.
Lewy bodies, a pathological hallmark of Parkinson’s disease, have been found in autonomic regulatory regions of the brain or peripheral autonomic ganglia in PD patients.18 And, many studies have shown the evidence of cardiac sympathetic denervation in early PD patients by using cardiac sympathetic imaging.19,20
Symptoms of autonomic dysfunction in PD patients were known to be related with older age, long disease duration, severe disease stage and anti-parkinsonian medication.7 However, Allcock et al. showed that frequency of OH was independent of duration and severity of movement symptoms in the study of the frequency of OH in a community-based cohort of PD patients.13 The prevalence of OH in PD was variable according to criteria and methods. In 5 relatively large studies involving more than 80 patients each, the frequency of OH ranged from 30% to 58%.6 Bonuccelli et al.21 showed the high prevalence of OH in de novo PD patients. In our study, prevalence of OH in the drug-naïve PD patients was moderate (18/45 patients, 40%), and similarly shown in the patients without comorbid disease (9/23 patient, 39.1%). Patients with OH were young and showed a short duration of disease, but those differences did not reach statistical significance, and the severity of parkinsonian symptoms was similar to those of patients without OH. The presence or severity of dysautonomic symptoms was not different between patients with or without OH, even in the cardiovascular domain. Therefore, OH did not respect the severity or distribution of other autonomic symptoms. Actually, the complaint of orthostasis was made by only six patients (13.3%), four of those patients showed OH. Most patients with OH did not complain of orthostasis, and Steven et al. showed that the majority of patients with profound orthostatic hypotension either did not show the typical symptoms (33%), or showed only atypical symptoms (24%).22 The unawareness of orthostatic hypotension stresses the importance of blood pressure monitoring irrelevant to complaints of patients.
Although we could not find statistical significance, patients with urinary incontinence were much higher in OH group (27.8% vs. 7.4%). This finding suggests that those patients can be diagnosed as multiple system atrophy (MSA). We followed all the patients more than six months and confirmed the good response to dopaminergic treatment. Because some patients with MSA show good response to treatment in early period, we could not exclude the possibility of MSA. Further studies with longer period of observation and about the change of dysautonomic symptoms along the disease course are warranted.
Although pathological implications of autonomic dysfunctions in PD patients have not been established yet, clinical implications can be significant enough to impact the daily activities of PD patients. Furthermore, most patients do not complain of noticeable symptoms, and the unawareness of patients warrants careful evaluation. Appropriate management of OH can prevent further insult and can improve daily activities of PD patients.

The author has no financial conflicts of interest.

Table 1
Autonomic dysfunction questionnaire
Gastrointestinal symptoms Urinary symptoms Sexual dysfunction Cardiovascular symptoms Thermoregulatory symptoms
Salivation Hesitancy Erectile dysfunction Orthostasis Sweating (Face)
Dysphagia Urgency Ejaculation difficulty Syncope Sweating (Trunk)
Nausea Incomplete voiding Libido change Sweating (Limb)
Constipation Weak stream Heat intolerance
Defecatory dysfunction (anismus) Frequency Cold intolerance
Nocturia Oiliness & seborrhea
Urinary incontinence
Table 2
Demographic & parkinsonian features in each group
Group Patients with orthostatic hypotension (n = 18) Patients without orthostatic hypotension (n = 27) p
Sex (M : F) 8 : 10 9 : 18 NS
Age (Y) 61.3 ± 10.8 65.5 ± 9.4 NS
Duration of symptoms (M) 13.8 ± 10.1 16.1 ± 15.9 NS
Duration of education (y) 8.0 ± 3.9 5.9 ± 4.6 NS
Comorbid disorders 9 (50.0%) 13 (48.1%) NS
UPDRS Part I 2.7 ± 1.5 2.4 ± 1.5 NS
UPDRS Part II 9.0 ± 4.5 9.1 ± 3.7 NS
UPDRS Part III 24.3 ± 7.7 26.5 ± 8.9 NS
UPDRS total 36.7 ± 10.5 38.2 ± 11.8 NS
Hoehn & yahr stage 2.0 ± 0.6 2.0 ± 0.5 NS
SEADL 73.3 ± 11.5 75.4 ± 11.2 NS

K-MMSE: Korean version of mini-mental status exam, ADL: activity of daily living, SEADL: schwab and england activity of daily living

Table 3
Presence of dysautonomic symptoms in each group
Patients with orthostatic hypotension (n = 18) Patients without orthostatic hypotension (n = 27) p
Gastrointestinal symptom
 Salivation 27.8% (5) 25.9% (7) NS
 Dysphagia 11.1% (2) 14.8% (4) NS
 Nausea 22.2% (4) 25.9% (7) NS
 Constipation 44.4% (8) 25.9% (7) NS
 Anismus 27.8% (5) 11.1% (3) NS
Urinary symptom
 Hesitancy 33.3% (6) 29.6% (8) NS
 Urgency 27.8% (5) 33.3% (9) NS
 Incomplete voiding 38.9% (7) 44.4% (12) NS
 Weak stream 38.9% (7) 33.3% (9) NS
 Frequency 77.8% (14) 66.7% (18) NS
 Nocturia 72.2% (13) 74.1% (20) NS
 Incontinence 27.8% (5) 7.4% (2) NS
Sexual dysfunction
 Erectile dysfunction* 37.5% (3/8) 22.2% (2/9) NS
 Ejaculation difficulty* 37.5% (3/8) 33.3% (3/9) NS
 Change of libido 50.0% (9) 40.7% (11) NS
Cardiovascular symptom
 Orthostasis 22.2% (4) 7.4% (2) NS
 Syncope 11.1% (2) 0.0% (0) NS
Thermoregulatory symptom
 Sweat 11.1% (2) 11.1% (3) NS
 Heat intolerance 11.1% (2) 11.1% (3) NS
 Cold intolerance 5.6% (1) 0.0% (0) NS
 Oiliness of skin 11.1% (2) 0.0% (0) NS

* evaluated male patients only

Table 4
Severity of dysautonomic symptoms in each group
Patients with orthostatic hypotension (n = 18) Patients without orthostatic hypotension (n = 27) p
Gastrointestinal symptom
 Salivation 0.2 ± 0.4 0.4 ± 0.4 NS
 Dysphagia 0.2 ± 0.5 0.2 ± 0.7 NS
 Nausea 0.2 ± 0.4 0.3 ± 0.5 NS
 Constipation 0.8 ± 1.1 0.2 ± 0.4 NS
 Anismus 0.5 ± 0.9 0.2 ± 0.5 NS
 Sum 2.1 ± 2.7 1.4 ± 1.8 NS
Urinary symptom
 Hesitancy 0.6 ± 1.2 1.0 ± 1.6 NS
 Urgency 0.6 ± 1.2 0.8 ± 1.4 NS
 Incomplete voiding 1.1 ± 1.9 1.2 ± 1.6 NS
 Weak stream 1.2 ± 1.9 1.2 ± 1.2 NS
 Frequency 1.7 ± 1.8 1.5 ± 1.4 NS
 Nocturia 1.8 ± 1.5 1.5 ± 0.9 NS
 Incontinence 0.5 ± 0.8 0.1 ± 0.4 NS
 Sum 7.7 ± 7.9 7.2 ± 6.5 NS
Sexual dysfunction
 Erectile dysfunction 0.6 ± 1.4 0.3 ± 0.9 NS
 Ejaculation difficulty 0.6 ± 1.5 0.4 ± 1.0 NS
 Change of libido 1.8 ± 1.9 1.4 ± 1.8 NS
 Sum 3.2 ± 4.2 2.3 ± 3.4 NS
Cardiovascular symptom
 Orthostasis 0.5 ± 0.9 0.1 ± 0.3 NS
 Syncope 0.0 ± 0.0 0.0 ± 0.0 NS
 Sum 0.8 ± 1.5 0.2 ± 0.5 NS
Thermoregulatory symptom
 Sweat 0.4 ± 1.0 0.0 ± 0.0 NS
 Heat intolerance 0.1 ± 0.3 0.2 ± 0.6 NS
 Cold intolerance 0.4 ± 1.0 0.0 ± 0.0 NS
 Oiliness of skin 0.1 ± 0.3 0.0 ± 0.0 NS
 Sum 1.1 ± 2.6 0.8 ± 2.2 NS
Total score 15.0 ± 15.4 11.7 ± 9.5 NS
  • 1. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2007;13:323–332.ArticlePubMed
  • 2. Cheon SM, Park MJ, Kim WJ, Kim JW. Non-motor off symptoms in Parkinson’s disease. J Korean Med Sci 2009;24:311–314.ArticlePubMedPMC
  • 3. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002;8:277–284.ArticlePubMed
  • 4. Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 2008;266:216–228.ArticlePubMed
  • 5. Senard JM, Raï S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63:584–589.ArticlePubMedPMC
  • 6. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res 2006;16:46–54.ArticlePubMed
  • 7. van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RA. Autonomic nervous system dysfunction in Parkinson’s disease: relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry 1993;56:1090–1095.ArticlePubMedPMC
  • 8. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol 2000;57:1461–1463.ArticlePubMed
  • 9. Calne DB, Brennan J, Spiers AS, Stern GM. Hypotension caused by L-dopa. Br Med J 1970;21:474–475.ArticlePubMedPMC
  • 10. Schoenberger JA. Drug-induced orthostatic hypotension. Drug Saf 1991;6:402–407.ArticlePubMed
  • 11. Montastruc JL, Chamontin B, Rostin M, Rascol O, Valet P, Gaillard G, et al. Experimental and clinical approaches to treatment of hypertension by dopamine receptor agonists. Clin Exp Hypertens A 1987;9:1069–1084.ArticlePubMed
  • 12. Lang AE. Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy. Arch Neurol 2001;58:835.Article
  • 13. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:1470–1471.ArticlePubMedPMC
  • 14. Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson’s disease. Int Neurosci 1994;74:9–16.Article
  • 15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.ArticlePubMedPMC
  • 16. Szil-Töö T, Kámá J, Paprika D, Dibó Rósa Z, Rudas L. Depressed baroreflex sensitivity in patients with Alzheimer’s and Parkinson’s disease. Neurobiol Aging 2001;22:435–438.ArticlePubMed
  • 17. Ziemseen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson’s disease. J Neurol Sci 2010;289:74–80.ArticlePubMed
  • 18. Walter BL. Cardiovascular autonomic dysfunction in patients with movement disorders. Cleve clin J Med 2008;75:54–58.Article
  • 19. Shin DH, Lee PH, Bang OY, Joo IS, Huh K. Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes. J Clin Neurol 2006;2:51–57.ArticlePubMedPMC
  • 20. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 2003;18:890–897.ArticlePubMed
  • 21. Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, et al. Orthostatic hypotension in de Novo parkinson’s disease. Arch Neurol 2003;60:1400–1404.ArticlePubMed
  • 22. Arbogast SD, Alshekhlee A, Hussain Z, McNeeley K, Chelimsky TC. Hypotension unawareness in profound orthostatic hypotension. Am J Med 2009;122:574–580.ArticlePubMed

Figure & Data



    Citations to this article as recorded by  
    • Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation
      Khaled Radad, Rudolf Moldzio, Christopher Krewenka, Barbara Kranner, Wolf-Dieter Rausch
      Exploration of Neuroprotective Therapy.2023; : 24.     CrossRef
    • Central retinal microvasculature damage is associated with orthostatic hypotension in Parkinson’s disease
      Jong Hyeon Ahn, Min Chae Kang, Dongyoung Lee, Jin Whan Cho, Kyung-Ah Park, Jinyoung Youn
      npj Parkinson's Disease.2023;[Epub]     CrossRef
    • Pronounced Orthostatic Hypotension in GBA-Related Parkinson’s Disease
      Tatiana Usnich, Henrike Hanssen, Katja Lohmann, Christina Lohse, Christine Klein, Meike Kasten, Norbert Brüggemann
      Journal of Parkinson's Disease.2022; 12(5): 1539.     CrossRef
    • Could Small Heat Shock Protein HSP27 Be a First-Line Target for Preventing Protein Aggregation in Parkinson’s Disease?
      Javier Navarro-Zaragoza, Lorena Cuenca-Bermejo, Pilar Almela, María-Luisa Laorden, María-Trinidad Herrero
      International Journal of Molecular Sciences.2021; 22(6): 3038.     CrossRef
    • Delayed orthostatic hypotension in Parkinson’s disease
      Sang-Won Yoo, Joong-Seok Kim, Ji-Yeon Yoo, Eunkyeong Yun, Uicheul Yoon, Na-Young Shin, Kwang-Soo Lee
      npj Parkinson's Disease.2021;[Epub]     CrossRef
    • Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study
      Francesca Baschieri, Luisa Sambati, Pietro Guaraldi, Giorgio Barletta, Pietro Cortelli, Giovanna Calandra-Buonaura
      Parkinsonism & Related Disorders.2021; 93: 12.     CrossRef
    • Trajectory Analysis of Orthostatic Hypotension in Parkinson’s Disease: Results From Parkinson’s Progression Markers Initiative Cohort
      Kui Chen, Kangshuai Du, Yichen Zhao, Yongzhe Gu, Yanxin Zhao
      Frontiers in Aging Neuroscience.2021;[Epub]     CrossRef
    • Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment
      Zhichun Chen, Guanglu Li, Jun Liu
      Neurobiology of Disease.2020; 134: 104700.     CrossRef
    • Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease
      Cecilia Quarracino, Matilde Otero-Losada, Francisco Capani, Santiago Pérez-Lloret
      Clinical Autonomic Research.2020; 30(3): 265.     CrossRef
    • Orthostatic hypotension in Parkinson disease
      Ylva Hivand Hiorth, Kenn Freddy Pedersen, Ingvild Dalen, Ole-Bjørn Tysnes, Guido Alves
      Neurology.2019;[Epub]     CrossRef
    • The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review
      Panagiotis Zis, Roberto Erro, Courtney C Walton, Anna Sauerbier, Kallol Ray Chaudhuri
      npj Parkinson's Disease.2015;[Epub]     CrossRef
    • Orthostatic Hypotension and Cognitive Impairment in <i>De Novo</i> Patients with Parkinson’s Disease
      Hyo-Jin Bae, Jun-Ho Lim, Sang-Myung Cheon
      Journal of Movement Disorders.2014; 7(2): 102.     CrossRef

    Comments on this article

    Add a comment

    JMD : Journal of Movement Disorders Twitter